GLP-1 AND GIP AGONISTS: A NEW THERAPEUTIC APPROACH FOR ENDOMETRIOSIS

In: Open Minds International Journal · 2026 · vol. 2(17) , pp. 1–5 · doi:10.22533/at.ed.51572172608095 · W7214937049
Review OA: diamond CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-10-26 ⓘ

This narrative review discusses how GLP-1 and GIP agonists may serve as a new therapeutic strategy for endometriosis by reducing inflammation, modulating immune response, controlling metabolism, and slowing lesion progression.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-26 · read from full text ⓘ

This narrative review examines the potential therapeutic role of GLP-1 and GIP receptor agonists in managing endometriosis by leveraging their anti-inflammatory, immunomodulatory, and metabolic properties. The authors analyze preclinical data and pathophysiological mechanisms to suggest that these agents may reduce systemic inflammation, modulate immune responses, and alleviate chronic pelvic pain associated with the disease. However, the paper explicitly notes a significant limitation: there is currently a lack of randomized clinical trials directly evaluating efficacy, safety, or lesion regression in patients with endometriosis. This paper is centrally about endometriosis — specifically proposing incretin mimetics as a novel pharmacological strategy to address its inflammatory and metabolic components.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a chronic, inflammatory, estrogen-dependent gynecological disease that affects approximately 10% of women of reproductive age and is a major cause of chronic pelvic pain, infertility, and reduced quality of life.Although conventional treatments are based primarily on hormonal therapies and surgical approaches, many cases present with symptom recurrence or therapeutic limitations.Recently, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists-widely used in the treatment of obesity and type 2 diabetes mellitus-have attracted interest due to their anti-inflammatory, immunomodulatory, and metabolic effects.The present study aims to discuss the potential mechanisms by which GLP-1 and GIP agonists may represent a new therapeutic strategy for endometriosis.This is a narrative review of the literature based on recent publications regarding the pathophysiology of endometriosis, systemic inflammation, insulin resistance, obesity, and the actions of incretin mimetics.The findings suggest that these medications may help reduce the inflammatory process, modulate the immune response, control metabolism, and slow the progression of endometriotic lesions.Although clinical evidence is still limited, preliminary results point to a promising area of research that could expand the therapeutic options available to patients with endometriosis.
Full text 12,836 characters · extracted from oa-pdf · 7 sections · click to expand

Abstract

Endometriosis is a chronic, in - flammatory, estrogen-dependent gyneco - logical disease that affects approximately 10% of women of reproductive age and is a major cause of chronic pelvic pain, infer- tility, and reduced quality of life. Althou - gh conventional treatments are based pri - marily on hormonal therapies and surgical approaches, many cases present with symp- tom recurrence or therapeutic limitations. Recently, glucagon-like peptide-1 (GLP- 1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists—wi - dely used in the treatment of obesity and type 2 diabetes mellitus—have attracted interest due to their anti-inflammatory, immunomodulatory, and metabolic effects. The present study aims to discuss the poten- tial mechanisms by which GLP-1 and GIP agonists may represent a new therapeutic strategy for endometriosis. This is a narra- tive review of the literature based on recent publications regarding the pathophysiology of endometriosis, systemic inflammation, insulin resistance, obesity, and the actions of incretin mimetics. The findings suggest that these medications may help reduce the inflammatory process, modulate the immune response, control metabolism, and slow the progression of endometriotic lesions. Although clinical evidence is still limited, preliminary results point to a pro- mising area of research that could expand the therapeutic options available to patients with endometriosis.

Keywords

Endometriosis; GLP-1; GIP; Tirzepatide; Semaglutide; Inflammation; Women’s Health.

Introduction

Endometriosis is a chronic inflamma- tory condition characterized by the pre - sence of endometrium-like tissue outside the uterine cavity, primarily affecting the ovaries, pelvic peritoneum, and uterosacral ligaments. It is estimated that the disease affects approximately 190 million women worldwide, representing a significant pu - blic health problem. Despite its high prevalence, the pa - thophysiology of endometriosis remains complex and multifactorial, involving hormonal, genetic, immunological, and inflammatory changes. The peritoneal en- vironment of patients exhibits increased production of pro-inflammatory cytokines, angiogenic factors, and pain mediators, which promote the survival and prolifera- tion of endometriotic implants. In recent decades, numerous studies have demonstrated the close relationship between systemic inflammation, energy metabolism, and gynecological diseases. At the same time, the development of GLP- 1 receptor agonists and dual GLP-1/GIP agonists has revolutionized the treatment of obesity and type 2 diabetes mellitus, showing benefits that extend beyond glyce- mic control. In addition to significant weight loss, medications such as semaglutide, liragluti- de, and tirzepatide exhibit anti-inflamma- tory, antioxidant, and immunomodulatory properties, sparking interest in their applica- tion for chronic inflammatory conditions. In this context, the hypothesis arises that such agents may also exert beneficial effects on the pathophysiology of endometriosis. DOI https:/ /doi.org/10.22533/at.ed.51572172608095 Article 5 GLP-1 AND GIP AGONISTS: A NEW THERAPEUTIC APPROACH FOR ENDOMETRIOSIS 3

Objective

T o analyze the available scientific evi- dence on the potential benefits of GLP-1 receptor agonists and dual GLP-1/GIP agonists in the treatment of endometriosis, discussing their pathophysiological mecha- nisms and future therapeutic prospects. METHODOLOGY This is a narrative literature review. We searched for publications indexed in the PubMed, Scopus, Web of Science, and Virtual Health Library (BVS) databases, using the following search terms in English and Portuguese: “Endometriosis,” “GLP- 1 receptor agonists,” “GIP ,” “Tirzepatide,” “Semaglutide,” “Inflammation,” “Obesity,” “Metabolic Dysfunction,” and “Women’s Health.” Original articles, systematic reviews, meta-analyses, and experimental studies pu- blished between 2015 and 2025 were inclu- ded. The selection prioritized studies related to the inflammatory pathophysiology of endometriosis, the mechanisms of action of GLP-1 and GIP agonists, and the potential applications of these drugs in inflammatory and gynecological diseases. Following a critical analysis of the lite- rature, the data were organized into thema- tic categories to discuss the main mechanis- ms involved.

Discussion

Endometriosis as a Systemic Inflammatory Disease The contemporary view of endome - triosis goes beyond the concept of an exclu- sively gynecological disease. It is now recog- nized that the condition involves a persistent systemic inflammatory state, characterized by elevated levels of pro-inflammatory cy - tokines such as TNF- α, IL-1 β, IL-6, and IL-8. These mediators promote angiogene- sis, cell proliferation, and neuronal sensiti- zation, contributing to chronic pain and the progression of lesions. Furthermore, immu- nological alterations facilitate evasion of cellular surveillance mechanisms, allowing ectopic implants to persist. This inflammatory scenario represents a potential therapeutic target for new phar- macological approaches. The Relationship Between Metabolism, Obesity, and Endometriosis Although endometriosis has traditio - nally been associated with women with a lower body mass index, recent studies de - monstrate a complex interaction between energy metabolism, insulin resistance, and inflammation. Obesity promotes increased produc - tion of inflammatory adipokines, including leptin and resistin, as well as reduced adi - ponectin levels, thereby fostering a syste - mic pro-inflammatory state. These factors may exacerbate pain, fatigue, and disease progression. DOI https:/ /doi.org/10.22533/at.ed.51572172608095 Article 5 GLP-1 AND GIP AGONISTS: A NEW THERAPEUTIC APPROACH FOR ENDOMETRIOSIS 4 Additionally, metabolic changes can directly influence the activity of macropha- ges and immune cells present in the perito- neal microenvironment, contributing to the maintenance of chronic inflammation. Mechanisms of Action of GLP-1 Agonists GLP-1 is an incretin hormone pro - duced by intestinal L cells in response to food intake. Its agonists promote increased insulin secretion, reduced glucagon levels, delayed gastric emptying, and increased satiety. However, recent studies show that the benefits of these medications extend beyond metabolic control. Several studies have identified anti-inflammatory properties as- sociated with reduced expression of TNF-α, IL-6, and C-reactive protein. Furthermore, GLP-1 agonists appe - ar to modulate macrophage activity, redu - cing polarization toward pro-inflammatory phenotypes and promoting a less aggressive immune environment. These mechanisms may be particularly relevant in endometriosis, whose progres - sion depends on the maintenance of a per- sistent inflammatory state. The Potential of Dual GLP-1/GIP Agonists Tirzepatide, the first dual GLP-1/GIP agonist approved for the treatment of obesi- ty and type 2 diabetes, demonstrates supe- rior results in reducing body weight and im- proving metabolic markers when compared to standalone GLP-1 agonists. GIP also performs important immu - nometabolic functions, influencing the re- gulation of inflammation and energy me - tabolism. Experimental studies suggest that the combined activation of GLP-1 and GIP receptors may potentiate systemic anti-in - flammatory effects. Although there are still no robust cli- nical trials directly evaluating tirzepatide in patients with endometriosis, the observed biological mechanisms suggest a potential benefit in reducing the disease’s inflamma- tory activity. Impact on Pain and Quality of Life Chronic pelvic pain is the main symp- tom of endometriosis and is closely linked to neuroinflammation. Recent evidence shows that GLP-1 agonists may exert neu- roprotective and pain-modulating effects by reducing inflammatory mediators and oxi- dative stress. In addition, the significant weight loss observed with these medications may improve physical and psychological aspects that are often compromised in women with endometriosis, including fatigue, self-este - em, sleep quality, and mental health. Therefore, the potential benefits of these drugs may extend beyond the reduc- tion of lesions to encompass an overall im- provement in quality of life. Current Limitations of the Evidence Despite growing scientific interest, the use of GLP-1 and GIP agonists in endome- triosis is still in the early stages of research. Much of the available evidence derives from experimental studies, animal models, and pathophysiological extrapolations. DOI https:/ /doi.org/10.22533/at.ed.51572172608095 Article 5 GLP-1 AND GIP AGONISTS: A NEW THERAPEUTIC APPROACH FOR ENDOMETRIOSIS 5 There is a lack of randomized clinical trials that directly evaluate outcomes such as pain reduction, lesion regression, impact on fertility, and improvement in quality of life in patients with endometriosis. Thus, although the results are promi- sing, it is not yet possible to routinely re - commend these therapies for the treatment of the disease outside of research protocols or approved indications for obesity and diabetes.

Conclusion

Endometriosis is a complex inflamma- tory disease that continues to pose a signifi- cant therapeutic challenge. GLP-1 receptor agonists and dual GLP-1/GIP agonists are emerging as potential therapeutic alternati- ves due to their anti-inflammatory, immu- nomodulatory, metabolic, and neuroprotec- tive effects. The pathophysiological mechanisms involved suggest that these medications may act on multiple aspects of the disease, including reducing systemic inflammation, modulating the immune system, improving energy metabolism, and potentially allevia- ting chronic pain. Although the current evidence is still preliminary, the growing number of studies points to a new and promising line of resear- ch in the treatment of endometriosis. Future clinical trials will be essential to determine the efficacy, safety, and applicability of these agents in gynecological practice.

References

Agarwal SK, Chapron C, Giudice LC, et al. Clinical diagnosis of endometriosis: a call to action. American Journal of Obstetrics and Gynecology. 2019;220(4):354.e1-354.e12. Bulun SE. Endometriosis. New England Jour- nal of Medicine. 2009;360(3):268-279. Chapron C, Marcellin L, Borghese B, Santulli P . Rethinking mechanisms, diagnosis and ma- nagement of endometriosis. Nature Reviews Endocrinology. 2019;15(11):666-682. Giudice LC. Endometriosis. New England Journal of Medicine. 2010;362(25):2389-2398. Kakoly NS, Moran LJ, Teede HJ, Joham AE. Cardiometabolic risks in women with en - dometriosis. Human Reproduction Update. 2018;24(5):553-568. Muller TD, Finan B, Bloom SR, et al. Gluca - gon-like peptide 1 (GLP-1). Molecular Meta- bolism. 2019;30:72-130. Nanda S, Jain A, Marwah N. Anti-inflamma- tory effects of GLP-1 receptor agonists: current evidence and future directions. Diabetes Re - search and Clinical Practice. 2023;198:110609. Surrey E, Taylor HS, Giudice LC, et al. Lon - g-term outcomes of endometriosis manage - ment. Fertility and Sterility. 2024;121(1):23- 35. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. Ferrero S, Barra F , Leone Roberti Maggiore U. Current and emerging therapeutics for endo- metriosis. Expert Opinion on Pharmacothera- py. 2023;24(8):903-916.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-pdf ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (6)

Source provenance

openalex
last seen: 2026-11-19T06:04:33.792782+00:00
License: CC0 · commercial use OK